Roche to present new data on 27 different medicines at ASCO
Basel, 14 May 2014
- Roche to deliver new data on approved medicines, investigational targeted combinations and the emerging pipeline
- Data in more than 19 tumor types will be presented, including new results from the investigational cancer immunotherapy MPDL3280A (anti-PDL1) in advanced bladder cancer and the Bcl-2 inhibitor GDC-0199/ABT-199 in hematology
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting. Of the more than 320 abstracts on Roche medicines, more than 40 have been accepted for oral presentation during the ASCO Annual Meeting.
“Since the first ASCO annual meeting 50 years ago, we are proud to have contributed practice-changing advances for people with a broad range of tumors including breast, blood, colorectal, lung, and skin cancers,” said Sandra Horning, Chief Medical Officer and Head, Global Product Development. “Data from 9 approved and 18 investigational medicines, such as our anti-PDL1 immunotherapy, at ASCO this year demonstrate our continued commitment to improve outcomes for people with cancer.”
The data to be presented at ASCO show the depth and strength of Roche’s oncology pipeline and include the following highlights:
Cancer Immunotherapy: A phase 1 study of anti-PDL1 in advanced bladder cancer will be presented in an oral session on Saturday 31 May. The presentation will feature important updates including; overall response rate, biomarker and safety information. As part of Roche’s global development plan to explore the potential of multiple immunotherapy targets in oncology, anti-PDL1 represents Roche’s most advanced investigational cancer immunotherapy in development.
Hematology: In addition to data from Roche’s anti-CD20 medicines MabThera/Rituxan (rituximab) and Gazyva (obinutuzumab), new data from two investigational medicines will be presented for the first time at ASCO. These data include interim results of a phase 1b study of the Bcl-2 inhibitor GDC-0199/ABT-199 in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia and results of a phase 2 study of polatuzumab vedotin, an anti-CD79b antibody drug conjugate in relapsed/refractory non-Hodgkin lymphoma.
|Medicine||Description of study||Abstract number|
|MPDL3280A (anti-PDL1) (investigational)||Inhibition of PD-L1 by MPDL3280A in patients with metastatic urothelial bladder cancer (UBC).||Abstract #5011|
|Avastin (bevacizumab)||CALGB/SWOG 80405: Findings from a phase 3 study comparing chemotherapy in combination with bevacizumab or cetuximab - in first-line treatment of metastatic colorectal cancer without KRAS mutations.||Abstract #LBA3|
|Avastin +Tarceva (erlotinib) (investigational)||Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC): An open-label randomized trial.||Abstract #8005|
|Erivedge (vismodegib)||Long-term safety profile and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.||Abstract #9013|
|GDC-0199/ABT-199 (investigational)||ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.||Abstract #7013|
|Polatuzumab vedotin (anti-CD79b antibody drug conjugate) and pinatuzumab vedotin (anti-CD22 antibody drug conjugate) (investigational)||Preliminary results of a phase 2 randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).||Abstract #8519|
|Zelboraf (vemurafenib) (investigational)||VE-BASKET, a first-in-kind, phase 2, histology-independent "basket" study of vemurafenib (VEM) in non-melanoma solid tumors harboring BRAF V600 mutations (V600m).||Abstract #2533|
|Zelboraf (vemurafenib)+ cobimetinib (investigational)||Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.||Abstract #9006|
2014 marks the 50 year anniversary of ASCO. Since the first ASCO Annual Meeting in 1964, Roche medicines have been discussed in thousands of data presentations, including eight plenary presentations since 2010, representing a significant contribution for people with many forms of cancer.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.